EUVIMEDEUVIMED entdecken
Crossref

Quantitation of Tucatinib, a Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC‐ESI‐MS/MS: Application to a Pharmacokinetic Study in Mice

Abhishek Dixit iD, Arunava Das iD

Biomedical Chromatography · 2026-08 · 40 (8)

DOI: 10.1002/bmc.70527 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 22.06.2026. Verfasst von Abhishek Dixit und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, Mandsaur University, Mandsaur, Madhya Pradesh, India. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Pyridines, Quinazolines, Liquid Chromatography-Mass Spectrometry. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tucatinib (Irbinitinib, ARRY‐380), a potent oral, selective HER2 kinase inhibitor that the FDA, has approved for the treatment of HER2‐positive metastatic breast cancer and colorectal cancer. Tucatinib provides a powerful, targeted therapy for HER2‐positive cancers, showing substantial benefits in survival and disease control, especially for patients with difficult‐to‐treat brain metastases, extending options beyond standard chemotherapy. This research aimed to create and validate a new rapid, sensitive, and specific LC–MS/MS technique for measuring tucatinib in dried blood spots (DBS) from mice, with afatinib serving as an internal standard (IS) following regulatory guidelines in the linearity range from 0.178 to 1009 ng/mL ( r > 0.990). The chromatographic separation of tucatinib and IS was achieved using the Acquity BEH C18 column with an isocratic mobile phase at a flow rate of 0.6 mL/min within 1.15 min total run time and 2 μL injection volume. Detection and quantification of tucatinib and the IS was done by using a triple quadrupole mass spectrometer in multiple reaction monitoring (MRM) mode. Tucatinib remained stable under various storage conditions. Comparison of DBS versus plasma samples concentrations showed a strong correlation, suggesting that DBS can serve as a valid alternative to plasma for pharmacokinetic evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryPyridinesQuinazolinesLiquid Chromatography-Mass SpectrometryProtein Kinase InhibitorsDried Blood Spot TestingOxazolesAnimalsMiceReproducibility of ResultsLinear ModelsFemaleLimit of DetectionChromatography, LiquidSensitivity and SpecificitySpectrometry, Mass, Electrospray IonizationDrug Stability

Stichwörter der Autor:innen

DBSLC–MS/MSmethod validationpharmacokineticstucatinib

Substanzen

PyridinesQuinazolinestucatinibProtein Kinase InhibitorsOxazoles

Autor:innen und Institutionen

  • Department of Life Science, Mandsaur University, Mandsaur, Madhya Pradesh, India.

ORCID-Profile: Abhishek Dixit, Arunava Das

Zitieren

APA

Dixit, A., & Das, A. (2026). Quantitation of Tucatinib, a Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC‐ESI‐MS/MS: Application to a Pharmacokinetic Study in Mice. Biomedical Chromatography, 40(8). https://doi.org/10.1002/bmc.70527

Vancouver

Dixit A, Das A. Quantitation of Tucatinib, a Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC‐ESI‐MS/MS: Application to a Pharmacokinetic Study in Mice. Biomedical Chromatography. 2026;40(8). doi:10.1002/bmc.70527

BibTeX
@article{Dixit2026,
  author = {Dixit, Abhishek and Das, Arunava},
  title = {Quantitation of Tucatinib, a Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC‐ESI‐MS/MS: Application to a Pharmacokinetic Study in Mice},
  journal = {Biomedical Chromatography},
  year = {2026},
  volume = {40},
  number = {8},
  doi = {10.1002/bmc.70527}
}
Kostenlos starten →